Low influenza vaccine uptake in India despite high mortality rates; manufacturers scaling up production to meet growing ...

Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space ...

H5N1 influenza is evolving rapidly, weakening the effectiveness of existing antibodies and increasing its potential threat to ...

Modified live vaccines tend to produce slightly stronger and longer lasting immunity and may provide slightly higher fetal ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

Most pediatric transplant recipients who received live-attenuated viral vaccines after transplant developed protective ...

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

The fears over mRNA-vaccine grant cancellations come after NIH staff members were instructed to compile a list of grants for ...

Polio remains a debilitating disease with no cure. Vaccination efforts are crucial, with the oral polio vaccine being a vital ...

A vaccine kept patients free of pancreatic cancer for years, yet new reports say the NIH is advising against mentioning mRNA tech in grants.

Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...

Immunization rates are falling. Vaccine disinformation, uncertainty, and skepticism seem to be at historic highs, extending ...